Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Fig. 1

Venetoclax-resistant (VEN-RE) cells had hypermethylated genomes. a–d The indicated parental cells (dotted lines) and VEN-RE cells (solid lines) were treated with the indicated inhibitors for 48 h, then cell viability was determined by CellTiter-Glo assay. Luminescence reads were normalized to those of DMSO-treated control cells. Data are mean ± SD. a Results of viability assays for cells treated with 0–10 μM VEN. b Results of viability assays for cells treated with 0–2 μM of the BCL-2 inhibitor S55746. c Results of viability assays for cells treated with 0–10 μM of the BCL-2/BCL-XL inhibitor ABT-737. d Viability of MOLM-13 parental and VEN-RE exposed to AZA and subsequently treated with 0–10 μM VEN

Back to article page